![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
cambridgeRNS Number:3524I Cambridge Antibody Tech Group PLC 3 April 2000 Not for release, distribution or publication in or into the United States, Canada, Japan, Australia or the Republic of Ireland Enquiries: Cambridge Antibody Technology Group plc David Chiswell, John Aston or Rowena Gardner 01763 263 233 Deutsche Bank AG London Katy Wilcox 020 7 545 8000 Cazenove & Co. Tony Brampton or Louise Littlewood 020 7 588 2828 HCC de Facto Sue Charles, David Dible or Nikul Odedra 020 7 496 3300 CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC ("CAT") OPEN OFFER & INTERNATIONAL OFFERING: OFFER PRICE SET AT 1850P PER SHARE RAISING #90 MILLION BEFORE EXPENSES Melbourn, UK, 3 April 2000, Cambridge Antibody Technology (CAT.L) today announces that the Offer Price for the Open Offer & International Offering by Deutsche Bank AG London ("Deutsche Bank") and Cazenove & Co. ("Cazenove") has been set at 1850p per New Ordinary Share. Taking into account current market conditions, the demand for New Ordinary Shares in the Offers and the desire to create a strong aftermarket, the amount to be raised under the Offers has been reduced to #90 million. Entitlements of Qualifying Shareholders under the Open Offer have been scaled back accordingly. At the Extraordinary General Meeting of CAT held on Friday 31 March 2000, both the resolutions, including the resolution to approve the allotment of 1,670,000 Ordinary Shares to Human Genome Sciences, Inc in accordance with the terms of the HGS Subscription Agreement, were approved. As a result, the Non Pre-emptive Ordinary Shares were made available in the International Offering. 1,418,598 Ordinary Shares have been taken up by Qualifying Shareholders under the Open Offer. 2,475,497 shares not taken up in the Open Offer have been made available in the International Offering. An additional 970,770 Ordinary Shares are being issued under the International Offering. The Company has granted Deutsche Bank AG London ("Deutsche Bank") an option (the "Over-Allotment Option") to subscribe for up to 300,000 additional Ordinary Shares at the Offer Price. The stabilising manager is Deutsche Bank. Excluding the Over-Allotment Option, the total net proceeds of the Offers to the Company (after expenses) will be approximately #87 million. CAT intends to post a supplementary prospectus for the Open Offer to all subscribers under the Offers on or around 3 April 2000 containing pricing information in respect of the Offers. The Ordinary Shares to be issued under the Open Offer and International Offering will rank pari passu with existing Ordinary Shares in all respects and are expected to be admitted to the Official List of the London Stock Exchange at 8.00am on Tuesday 4 April 2000. Terms defined in the CAT press announcement dated 7 March 2000 shall have the same meaning in this announcement. This press release is not an offer of securities for sale in the United States. Any such securities may not be offered or sold in the United States absent registration or an exemption from registration. The issue of this announcement has been approved by the directors of Cambridge Antibody Technology Group plc who accept responsibility for the information contained in it. This announcement has been approved solely for the purposes of section 57 of the Financial Services Act 1986 by Deutsche Bank and Cazenove, both of which are regulated in the UK by The Securities and Futures Authority Limited. Deutsche Bank and Cazenove are acting for Cambridge Antibody Technology Group plc and no one else in connection with the Offers and will not be responsible to anyone other than Cambridge Antibody Technology Group plc for providing the protections afforded to customers of Deutsche Bank and Cazenove nor for providing advice in relation to the Offers. END MSCBGGDSCSGGGGD
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions